Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination
Omar Fueyo‐Rodríguez, Benjamín Valente-Acosta, Rodolfo Jiménez-Soto, Yvette Neme-Yunes, Sergio I. Inclán-Alarcón, Roxana Trejo-González, Miguel Ángel García Salcido
Abstract
Immune thrombocytopenia (ITP) has been widely reported as a complication of SARS-CoV-2 infection, but to our knowledge, there have been no reports on the association of the COVID-19 vaccine with thrombocytopenia. Here, we report a case of secondary ITP in a patient who was recently immunised with the messenger RNA COVID-19 vaccine BNT162b2 (Pfizer-BioNTech).
Topics & Concepts
Immune thrombocytopeniaCoronavirus disease 2019 (COVID-19)VaccinationMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakImmune systemComplicationVirologyImmunologyAntibodyInternal medicineOutbreakInfectious disease (medical specialty)DiseasePlatelet Disorders and TreatmentsHeparin-Induced Thrombocytopenia and ThrombosisBlood groups and transfusion